GLOBALT Investments LLC / GA 13F: New $1.8M Stake in AXSM
Key Points
- GLOBALT Investments LLC opened a new position with 9,507 shares of Axsome Therapeutics, representing a $1,752,996 investment.
- As of October 28, 2026, Axsome Therapeutics shares recently traded around $142.81, which is above the event close of $142.20 on October 27.
- The stock has a market cap of about $7.45 billion and is currently below its 50-day and 200-day moving averages.
Get Axsome Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $AXSM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Axsome Therapeutics, Inc. alert may contain errors. Disclosures
On October 27, 2026, GLOBALT Investments LLC took a new position in Axsome Therapeutics, acquiring 9,507 shares valued at $1,752,996. This information comes from the fund's latest Form 13F filing with the SEC.
AXSM
Axsome Therapeutics, Inc.
What Changed in GLOBALT Investments' Axsome Therapeutics Position
GLOBALT Investments opened a new position in Axsome Therapeutics, with its stake now totaling 9,507 shares. This move represents a significant investment for the fund, reflecting its interest in the biotechnology sector.
Where Axsome Therapeutics Fits in GLOBALT Investments' Portfolio
Axsome Therapeutics now makes up about 0.1% of GLOBALT Investments' reported portfolio, which ranks 39 out of 212 holdings. This new position is a fresh entry, suggesting a strategic bet on the company's future potential.
Other Institutional Activity in Axsome Therapeutics
Deep Track Capital, LP reduced its holdings by 399,937 shares, ending with 700,000 shares worth about $99.5 million. Meanwhile, Two Sigma Investments, LP increased its stake by 346,698 shares, bringing its total to 669,478 shares valued at approximately $95.2 million. These moves show varied strategies among institutional investors regarding Axsome Therapeutics.
Axsome Therapeutics, Inc. Stock Down 0.9%
As of October 28, 2026, Axsome Therapeutics shares traded recently around $142.81, which is above the event close of $142.20 on October 27. However, the stock is currently below its 50-day moving average of $188.97 and its 200-day average of $199.81, indicating some downward pressure over the medium term.
Recent Earnings
Axsome Therapeutics reported trailing twelve-month revenue of approximately $776.6 million, with a year-over-year growth rate of 45.5%. The company is set to announce its next earnings on November 2, 2026.
Insider Buying and Selling at Axsome Therapeutics, Inc.
Several insiders sold shares earlier this year, including Herriot Tabuteau, the CEO, who sold 49,664 shares at an average price of $240.25 on July 1, 2026, totaling about $11.9 million. Roger A. Jeffs, a director, sold 572 shares worth about $141,656 on June 11, 2026. These transactions indicate ongoing insider activity as the company continues to navigate its market.
Analysts Set New Price Targets
On September 23, 2026, Truist Securities maintained a Buy rating on the stock with a price target of $285.00, up from a prior target of $200.00. Deutsche Bank also maintained a Buy rating with a target of $267.00 on September 29, 2026. The consensus recommendation remains a strong Buy, with a mean price target of about $279.38 based on 21 analyst opinions.
About Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company based in New York that develops therapies for central nervous system disorders. The firm's innovative approach aims to address significant health challenges in this area, making it a key player in the biotech industry.
Bottom Line
Investors should keep an eye on Axsome Therapeutics as it approaches its next earnings report on November 2, 2026. With GLOBALT Investments' new position, it will be interesting to see how the stock performs in the coming months.
Related Filing Alerts
Source: GLOBALT Investments LLC / GA's 13F filing on $AXSM (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts